Media

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Press Release

2025

Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors

Shinobi Therapeutics

Publication

2025

1010 Systemic and regionally infused iPSC-derived CD8 αβ T cells mediate tumor killing via TCR- and innate receptor-dependent mechanisms enhanced by cytokine armoring

Shinobi Therapeutics, Journal for ImmunoTherapy of Cancer

News

2024

Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer

Endpoints News

News

2024

Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform

Fierce Pharma

News

2024

Shinobi recognized by Prime Minister Kishida as a leader in Japan's Biotech ecosystem at the Japan Innovation Luncheon

Prime Minister's Office of Japan

Press Release

2024

Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology

Anocca

Publication

2024

Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model

Shin Kaneko Lab, Cell Stem Cell

Press Release

2024

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology

Shinobi Therapeutics

Press Release

2024

Shinobi secures $59 million non-dilutive funding from AMED

Shinobi Therapeutics

Press Release

2024

Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic

Shinobi Therapeutics

News

2023

Shinobi raises $51M to take on cell therapy challenges with ex-Wugen CEO at helm, Carl June in support

Endpoints News

Press Release

2023

Shinobi closes Series A round with $51 Million

Shinobi Therapeutics

Publication

2023

Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity

Tobias Deuse Lab / Shinobi Therapeutics, Cell Stem Cell

Publication

2023

Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression

Tobias Deuse Lab, Nature

Publication

2021

Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells

Shin Kaneko Lab, Nature

Publication

2021

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy

Shin Kaneko Lab, Nature

Publication

2020

Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti–glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells

Shin Kaneko Lab, Cancer Sci

Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors

1010 Systemic and regionally infused iPSC-derived CD8 αβ T cells mediate tumor killing via TCR- and innate receptor-dependent mechanisms enhanced by cytokine armoring

Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer

Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform

Shinobi recognized by Prime Minister Kishida as a leader in Japan's Biotech ecosystem at the Japan Innovation Luncheon

Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology

Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology

Shinobi secures $59 million non-dilutive funding from AMED

Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic

Shinobi raises $51M to take on cell therapy challenges with ex-Wugen CEO at helm, Carl June in support

Shinobi closes Series A round with $51 Million

Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity

Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression

Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy

Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti–glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells

Join us in pioneering the next frontier of cell therapy